224 related articles for article (PubMed ID: 22014153)
1. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.
Filppula AM; Laitila J; Neuvonen PJ; Backman JT
Br J Pharmacol; 2012 Apr; 165(8):2787-98. PubMed ID: 22014153
[TBL] [Abstract][Full Text] [Related]
2. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
[TBL] [Abstract][Full Text] [Related]
3. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.
Nebot N; Crettol S; d'Esposito F; Tattam B; Hibbs DE; Murray M
Br J Pharmacol; 2010 Nov; 161(5):1059-69. PubMed ID: 20977456
[TBL] [Abstract][Full Text] [Related]
4. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors.
Filppula AM; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2014 Jul; 42(7):1202-9. PubMed ID: 24713129
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
6. Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials.
Wang Y; Wang M; Qi H; Pan P; Hou T; Li J; He G; Zhang H
Drug Metab Dispos; 2014 Apr; 42(4):782-95. PubMed ID: 24476576
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib.
Khan MS; Barratt DT; Somogyi AA
Xenobiotica; 2016; 46(3):278-87. PubMed ID: 26161459
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
Filppula AM; Mustonen TM; Backman JT
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):739-748. PubMed ID: 29956478
[TBL] [Abstract][Full Text] [Related]
9. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
Wang JS; DeVane CL
Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
[TBL] [Abstract][Full Text] [Related]
10. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
Zahno A; Brecht K; Bodmer M; Bur D; Tsakiris DA; Krähenbühl S
Br J Pharmacol; 2010 Sep; 161(2):393-404. PubMed ID: 20735423
[TBL] [Abstract][Full Text] [Related]
11. The tyrosine kinase inhibitor nilotinib selectively inhibits CYP2C8 activities in human liver microsomes.
Kim MJ; Lee JW; Oh KS; Choi CS; Kim KH; Han WS; Yoon CN; Chung ES; Kim DH; Shin JG
Drug Metab Pharmacokinet; 2013; 28(6):462-7. PubMed ID: 23629743
[TBL] [Abstract][Full Text] [Related]
12. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
Wang JS; Neuvonen M; Wen X; Backman JT; Neuvonen PJ
Drug Metab Dispos; 2002 Dec; 30(12):1352-6. PubMed ID: 12433802
[TBL] [Abstract][Full Text] [Related]
13. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.
Fang ZZ; Zhang YY; Ge GB; Huo H; Liang SC; Yang L
Br J Clin Pharmacol; 2010 Feb; 69(2):193-9. PubMed ID: 20233183
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.
van Erp NP; Gelderblom H; Karlsson MO; Li J; Zhao M; Ouwerkerk J; Nortier JW; Guchelaar HJ; Baker SD; Sparreboom A
Clin Cancer Res; 2007 Dec; 13(24):7394-400. PubMed ID: 18094422
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
[TBL] [Abstract][Full Text] [Related]
16. Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes.
Misaka S; Kawabe K; Onoue S; Werba JP; Giroli M; Tamaki S; Kan T; Kimura J; Watanabe H; Yamada S
Drug Metab Pharmacokinet; 2013; 28(3):244-9. PubMed ID: 23268924
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):493-8. PubMed ID: 25424246
[TBL] [Abstract][Full Text] [Related]
18. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
20. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation.
Projean D; Baune B; Farinotti R; Flinois JP; Beaune P; Taburet AM; Ducharme J
Drug Metab Dispos; 2003 Jun; 31(6):748-54. PubMed ID: 12756207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]